Type to search

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform | Pharmtech Focus
Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma | Pharmtech Focus
Antengene Announces XPOVIO ® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications | Pharmtech Focus